FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2176479197> ?p ?o ?g. }

• W2176479197 endingPage "4166" @default.
• W2176479197 startingPage "4155" @default.
• W2176479197 abstract "// Brian H. Kushner 1 , Irina Ostrovnaya 2 , Irene Y. Cheung 1 , Deborah Kuk 2 , Shakeel Modak 1 , Kim Kramer 1 , Stephen S. Roberts 1 , Ellen M. Basu 1 , Karima Yataghene 1 , Nai-Kong V. Cheung 1 1 Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 2 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Correspondence to: Brian H. Kushner, e-mail: kushnerb@mskcc.org Keywords: immunotherapy, anti-G D2 antibody, minimal residual disease, autologous stem-cell transplantation, pediatric oncology Received: September 08, 2015      Accepted: November 09, 2015      Published: November 26, 2015 ABSTRACT Since 2003, high-risk neuroblastoma (HR-NB) patients at our center received anti-G D2 antibody 3F8/GM-CSF + isotretinoin – but not myeloablative therapy with autologous stem-cell transplantation (ASCT). Post-ASCT patients referred from elsewhere also received 3F8/GM-CSF + isotretinoin. We therefore accrued a study population of two groups treated during the same period and whose consolidative therapy, aside from ASCT, was identical. We analyzed patients enrolled in 1st complete/very good partial remission (CR/VGPR). Their event-free survival (EFS) and overall survival (OS) were calculated from study entry. Large study size allowed robust statistical analyses of key prognosticators including MYCN amplification, minimal residual disease (MRD), FCGR2A polymorphisms, and killer immunoglobulin-like receptor genotypes of natural killer cells. The 170 study patients included 60 enrolled following ASCT and 110 following conventional chemotherapy. The two cohorts had similar clinical and biological features. Five-year rates for ASCT and non-ASCT patients were, respectively: EFS 65% vs. 51% ( p = .128), and OS 76% vs. 75% ( p = .975). In multivariate analysis, ASCT was not prognostic and only MRD-negativity after two cycles of 3F8/GM-CSF correlated with significantly improved EFS and OS. Although a trend towards better EFS is seen with ASCT, OS is near identical. Cure rates may be similar, as close surveillance detects localized relapse and effective salvage treatments are applied. ASCT may not be needed to improve outcome when anti-G D2 immunotherapy is used for consolidation after dose-intensive conventional chemotherapy." @default.
• W2176479197 created "2016-06-24" @default.
• W2176479197 creator A5016432846 @default.
• W2176479197 creator A5026950879 @default.
• W2176479197 creator A5031172839 @default.
• W2176479197 creator A5034081882 @default.
• W2176479197 creator A5034325765 @default.
• W2176479197 creator A5043729995 @default.
• W2176479197 creator A5050680844 @default.
• W2176479197 creator A5053307625 @default.
• W2176479197 creator A5058950476 @default.
• W2176479197 creator A5083817841 @default.
• W2176479197 date "2015-11-26" @default.
• W2176479197 modified "2023-09-27" @default.
• W2176479197 title "Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin" @default.
• W2176479197 cites W1519295343 @default.
• W2176479197 cites W1519875566 @default.
• W2176479197 cites W1535107443 @default.
• W2176479197 cites W1574327664 @default.
• W2176479197 cites W1575002436 @default.
• W2176479197 cites W1831803445 @default.
• W2176479197 cites W1917242018 @default.
• W2176479197 cites W1935226228 @default.
• W2176479197 cites W1940650862 @default.
• W2176479197 cites W1950984413 @default.
• W2176479197 cites W1951179504 @default.
• W2176479197 cites W1960710326 @default.
• W2176479197 cites W1970865970 @default.
• W2176479197 cites W1986399662 @default.
• W2176479197 cites W1993428519 @default.
• W2176479197 cites W1993954120 @default.
• W2176479197 cites W2001104808 @default.
• W2176479197 cites W2007680507 @default.
• W2176479197 cites W2019221801 @default.
• W2176479197 cites W2027657181 @default.
• W2176479197 cites W2029122407 @default.
• W2176479197 cites W2049208274 @default.
• W2176479197 cites W2051406185 @default.
• W2176479197 cites W2053748622 @default.
• W2176479197 cites W2063272562 @default.
• W2176479197 cites W2067590368 @default.
• W2176479197 cites W2068512864 @default.
• W2176479197 cites W2096398040 @default.
• W2176479197 cites W2099134748 @default.
• W2176479197 cites W2104684902 @default.
• W2176479197 cites W2106568960 @default.
• W2176479197 cites W2106664318 @default.
• W2176479197 cites W2106726143 @default.
• W2176479197 cites W2111733282 @default.
• W2176479197 cites W2112654701 @default.
• W2176479197 cites W2113695682 @default.
• W2176479197 cites W2120781745 @default.
• W2176479197 cites W2127775057 @default.
• W2176479197 cites W2130686884 @default.
• W2176479197 cites W2132154679 @default.
• W2176479197 cites W2135403187 @default.
• W2176479197 cites W2136462971 @default.
• W2176479197 cites W2136574608 @default.
• W2176479197 cites W2137648684 @default.
• W2176479197 cites W2137747512 @default.
• W2176479197 cites W2138216545 @default.
• W2176479197 cites W2143252790 @default.
• W2176479197 cites W2147800896 @default.
• W2176479197 cites W2151310238 @default.
• W2176479197 cites W2157124382 @default.
• W2176479197 cites W2157272402 @default.
• W2176479197 cites W2161798205 @default.
• W2176479197 cites W2327522594 @default.
• W2176479197 cites W2420990069 @default.
• W2176479197 cites W4234309009 @default.
• W2176479197 doi "https://doi.org/10.18632/oncotarget.6393" @default.
• W2176479197 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4826196" @default.
• W2176479197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26623730" @default.
• W2176479197 hasPublicationYear "2015" @default.
• W2176479197 type Work @default.
• W2176479197 sameAs 2176479197 @default.
• W2176479197 citedByCount "46" @default.
• W2176479197 countsByYear W21764791972016 @default.
• W2176479197 countsByYear W21764791972017 @default.
• W2176479197 countsByYear W21764791972018 @default.
• W2176479197 countsByYear W21764791972019 @default.
• W2176479197 countsByYear W21764791972020 @default.
• W2176479197 countsByYear W21764791972021 @default.
• W2176479197 countsByYear W21764791972022 @default.
• W2176479197 countsByYear W21764791972023 @default.
• W2176479197 crossrefType "journal-article" @default.
• W2176479197 hasAuthorship W2176479197A5016432846 @default.
• W2176479197 hasAuthorship W2176479197A5026950879 @default.
• W2176479197 hasAuthorship W2176479197A5031172839 @default.
• W2176479197 hasAuthorship W2176479197A5034081882 @default.
• W2176479197 hasAuthorship W2176479197A5034325765 @default.
• W2176479197 hasAuthorship W2176479197A5043729995 @default.
• W2176479197 hasAuthorship W2176479197A5050680844 @default.
• W2176479197 hasAuthorship W2176479197A5053307625 @default.
• W2176479197 hasAuthorship W2176479197A5058950476 @default.
• W2176479197 hasAuthorship W2176479197A5083817841 @default.
• W2176479197 hasBestOaLocation W21764791971 @default.
• W2176479197 hasConcept C121608353 @default.

• next